Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program

Atossa's Rare Pediatric Disease Designation for (Z)-endoxifen in neuromuscular diseases qualifies for a future PRV upon FDA approval SEATTLE, Feb. 5, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc.

Duchenne Progress Shows How the FDA Should Judge Orphan Drugs

A milestone in the treatment of Duchenne muscular dystrophy (DMD) passed recently with remarkably little public notice. That ...

Pitt study could lead to new way to lose weight

Doctors said the drugs can help people lose unwanted pounds while retaining muscle.
Le Lézard

Champion Insights Officially Opens Enrollment to Investigate ALS Risk in High-Performance Athletes, Military Members, and First Responders

Champion Insights officially commenced active research operations today in its nationwide study investigating why elite ...
ET HealthWorld

DUCHENNE MUSCULAR DYSTROPHY

ETHealthworld.com brings latest duchenne muscular dystrophy news, views and updates from all top sources for the Indian Health industry.
The Manila Times

RESTEM Announces First Patient Dosed in the Phase 2/3 IIMPACT Study of Restem-L in Idiopathic Inflammatory Myopathy

Initiation of the IIMPACT study follows promising Phase 1 results where Restem-L demonstrated clinically meaningful efficacy ...
Investing.com India

Cumberland Pharmaceuticals shares rise on FDA fast track status for DMD drug

Investing.com -- Shares of drugmaker Cumberland Pharmaceuticals (NASDAQ:CPIX) rose 15.04% to $4.36 on Wednesday after the ...
The Manila Times

Roche’s fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple sclerosis (PPMS)

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in ...
The Navhind Times

Designing change

Dr. Anjlee Agarwal, is a National Award recipient and a pioneer in universal accessibility and sustainable mobility. In conversation with The Navhind Times, ...
PharmiWeb

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease

The first-in-human clinical study of SRP-1005, known as INSIGHTT, is expected to begin in the second quarter of 2026CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the ...
Le Lézard

Genentech's Fenebrutinib Is the First Investigational Medicine in Over a Decade That Reduces Disability Progression in Primary Progressive Multiple Sclerosis (PPMS)

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton's tyrosine kinase (BTK ...

F. Hoffmann-La Roche Ltd: Roche's fenebrutinib is the first investigational medicine in over a decade that reduces disability progression in primary progressive multiple ...

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in reduc ...